

STIVARGA PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Date:		ation (required)		Provider Name:			
Patient Name:				Specialty:	N	NPI:	
Date of Birth:		Sex: □Male □Female		Office Phone:	Ot	Office Fax:	
Street Address:				Office Street Address:			
City:		State: Zip:		City:	State:	State: Zip:	
Patient ID:				Physician Signature:			
R	1 1	<u> </u>	HVSICIAN (COMPLETES			
	**Check v			regoratenid) which medication is part of the p d in its entirety for process		nefit	
Is this request for	_						
•	_	•		blets = 160mg daily)?	ta	ablet(s) per day	
1. Does the patier	· ·		ē				
•	C	•		ths, excluding samples? Plant	ase select	answer below:	
		of therapy, please a	answer the follo	wing questions:			
	the patient's diag	gnosis?					
	angiocarcinoma	-1 T (CICT)					
		al Tumor (GIST) nor unresectable,		cally advanced? □Yes □	■No		
	•			Bleevec (imatinib) and Sute		ib)? □Yes □No	
	tocellular Carcinolas the patient be		ted with sorafen	nib (Nexavar)? □Yes □1	No		
i. H	static Colorectal (las the patient bedhemotherapy?	en previously trea	ted with fluorop	oyrimidine-, oxaliplatin-and	irinotecar	n-based	
ii. Does the patient have RAS wild-type metastatic colorectal cancer? □Yes* □No							
	-		•	with an anti-EGFR therapy	√? □Yes	□No	
☐ Other	diagnosis (<i>pleas</i>	e specify):					
*If YI	ES, will the patie		nd bilirubin lev			ring the first two months of	
□ YES – this i	s a PA renewal for	or CONTINUAT	ION of therapy	, please answer the following	ng question	ns:	
a. What is	the patient's diag	gnosis?			-		
□Gastr		al Tumor (GIST)		a (HCC) ☐ Metastati cally advanced? ☐ Yes ☐		tal Cancer (CRC)	
	_						
b. Are the	patient's liver fu	nction tests (LFTs	s) less than 3 tin	nes the upper limit of norm	al (ULN) o	or baseline? □Yes □No	
c. Does the	e patient show sig	gns and symptom	s of gastrointest	inal perforation or fistula?	□Yes □	lNo	
d. Has the	patient develope	d Reversible Post	erior Leukoence	ephalopathy Syndrome (RP	LS)?	es □No	



STIVARGA PRIOR APPROVAL REQUEST

Send completed form to: Service Benefit Plan Prior Approval P.O. Box 52080 MC 139 Phoenix, AZ 85072-2080 Attn. Clinical Services Fax: 1-877-378-4727

Message:

Attached is a Prior Authorization request form.

For your convenience, there are 3 ways to complete a Prior Authorization request:

Electronically Online (ePA) Results in 2-3 minutes FASTEST AND EASIEST	Now you can get responses to drug prior authorization requests securely online. Online submissions may receive instant responses and do not require faxing or phone calls. Requests can be made 24 hours a day, 7 days a week. For more information on electronic prior authorization (ePA) and to register, go to Caremark.com/ePA.
Phone (4-5 minutes for response)	The FEP Clinical Call Center can be reached at (877)-727-3784 between the hours of 7AM-9PM Eastern Time. A live representative will assist with the Prior Authorization, asking for the same info contained on the attached form. Please review the form and have your answers ready for faster service. The process over the phone takes on average between 4 and 5 minutes.
Fax (3-5 days for response)	Fax the attached form to (877)-378-4727 Requests sent via fax will be processed and responded to within 5 business days. The form must be filled out completely, if there is any missing information the PA request cannot be processed. Please only fax the completed form once as duplicate submissions may delay processing times.

